Source comparison
PT-141 for HSDD Research: Dosing Comparison
Subcutaneous 1.75mg ~80% 45–60 minutes 25% composite endpoint vs 8% placebo (RECONNECT trials) Transient nausea (40%), injection-site reactions (5%) Intranasal (experimental) Variable (20–50%) 20–40 minutes Insufficient Phase 3 data; pilot studies suggest lowe
This comparison does not assign a generated winner or score.
- Subcutaneous 1.75mg
- ~80%
- 45–60 minutes
- 25% composite endpoint vs 8% placebo (RECONNECT trials)
- Transient nausea (40%), injection-site reactions (5%)
- Intranasal (experimental)
- Variable (20–50%)
- 20–40 minutes
- Insufficient Phase 3 data; pilot studies suggest lower efficacy than SC route
- Nasal mucosal irritation, inconsistent absorption across individuals
- Oral (not viable)
- <5%
- N/A
- Not clinically meaningful. Peptidase degradation prevents systemic exposure
- Oral PT-141 does not achieve therapeutic plasma concentrations
- Subcutaneous 0.75mg
- ~70%
- Below threshold for statistically significant FSFI-D improvement in Phase 2 trials
- Insufficient receptor occupancy for consistent CNS effects